Malignant hypertension (MHT) is a rare and severe form of hypertension characterised by arteriolar necrosis and severe vascular damage, leading to stroke, myocardial infarction and death. We hypothesised that in addition to endothelial damage, MHT may be associated with increased oxidative stress. Lipid hydroperoxides (LHP, an index of oxidative damage) and plasma von Willebrand factor (vWf, an index of endothelial damage/dysfunction) were measured in 16 patients with MHT and compared with 16 non-malignant essential hypertensives and 32 normotensive controls. vWf was greater in MHT (mean 117 iU/dL) than in non-malignant hypertensives (97 iU/dL) or normotensive controls (100 iU/dL) (ANOVA P = 0.017). However, although LHP were greater in MHT (mean 10.6 mol/L) than in normo-
Introduction
Malignant phase hypertension (MHT) is a form of severe hypertension, which is characterised by very high blood pressures with severe hypertensive retinopathy. The histological hallmark is fibrinoid necrosis of arterioles and severe vascular damage in many tissues including the kidney, and certainly, in early reports before the advent of modern antihypertensive therapy, around 80% of patients are dead within 2 years if the condition is left unrecognised or untreated. 1, 2 The importance of early diagnosis is emphasised as patients tend to develop clinical symptoms only at a late stage of their disease.
Whilst the prevalence and incidence of MHT is declining in many western countries, we have not noticed any decline in the number of new cases of MHT in our large city centre district general hospital serving a multiracial community of approximately 350 000 people, and have maintained a large database of these patients in the West Birmingham MHT project. [3] [4] [5] Many of the major complications of MHT, including stroke, myocardial infarction and heart failure, are pathophysiologically related to intravascular thrombosis.
We hypothesised that vascular damage in MHT may be mediated by an increase in oxidative stress. We therefore measured lipid hydroperoxides (LHP, an index of oxidative damage 6 ) and plasma von Willebrand factor (vWf, a well-established index of endothelial damage/dysfunction 7 ) in consecutive new presentations with MHT to our unit, and compared them with matched non-malignant essential hypertensives (EHT) and normotensive healthy controls.
Patients and methods

Subjects
Consecutive patients presenting to our unit with a diagnosis of MHT over a 15-month period (October 1998 to December 1999) were recruited. MHT was defined as the presence of raised blood pressure in association with bilateral linear or flame-shaped retinal haemorrhages and/or cotton-wool spots or hard exudates with or without papilloedema on fun-doscopy and retinal photography. [3] [4] [5] This definition therefore fulfils the existing criteria for MHT, which includes both Grades III ('accelerated hypertension') and Grade IV ('malignant hypertension') of the Keith, Wagener and Barker classification 1 : thus, our patients with MHT are essentially the 'acceleratedmalignant' hypertension group as used in some classifications. We would emphasise that previous research has clearly shown that these two retinopathy categories carry an equally bad prognosis, and thus both should be considered to be 'malignant' hypertension. 5 Blood pressure was measured at least twice on each occasion by specifically trained observers using a standard mercury sphygmomanometer, diastolic pressures being taken at the phase of disappearance of sounds (Korotkof phase V).
Blood samples were also taken from patients presenting to our outpatient hypertension clinic with newly diagnosed untreated non-malignant EHT (defined as resting blood pressures Ͼ160/90 mm Hg on three or more occasions, measured at the general practitioner, our outpatient hypertension clinic and confirmed yet again at our research clinic) who were age-and sex-matched (in an approximate 1:1 ratio). Patients with secondary hypertension were excluded from both the MHT and EHT groups. In addition, healthy normotensive controls (approximately one MHT: two controls) were recruited from the two local primary care (general practitioner) lists, as part of a community health screen survey. The patients with untreated nonmalignant essential hypertension and the normotensive controls were all free of diabetes mellitus and overt coronary, peripheral or cerebrovascular disease by careful clinical history and examination. Patients with underlying neoplastic, connective tissue, inflammatory or infective disorders, those taking antithrombotic therapy or hormone replacement therapy were also excluded. Informed consent was obtained and the protocol had been approved by the West Birmingham Local Research Ethics Committee.
Laboratory measurements
Blood samples were taken from an antecubital vein with minimal haemostasis, and centrifuged at 3000 g, 4°C for 20 min. Platelet-free plasma (for vWf) and serum (for LHP) was immediately separated and frozen at −70°C. vWf was measured using an established ELISA technique using commercial polyclonal antisera (Dako, High Wycombe, UK). LHP were measured by ferrous oxidation of xylenol orange. 6 Intra-and inter-assay coefficients of variation for all assays were Ͻ5% and Ͻ10% respectively.
Power calculation
We hypothesised that there would be a graded increased in levels of vWf between healthy controls, EHT and MHT. To be precise, that the level in EHT would be two-thirds of a standard deviation higher than in the healthy controls, and that levels would be a further two-thirds of one standard deviation increased in the patients with MHT. In order to achieve this we needed good data from 12 subjects per group to provide power of 0.80 for a difference of P Ͻ 0.05 by analysis of variance. However, as we intended to measure another variable (LHP) we increased our numbers of the two control groups accordingly.
Statistical analysis
Discrete variables are expressed as frequency (% of study group) and compared with 2 -tests. Continuous variables are expressed as mean (95% confidence interval) and compared using one-way ANOVA with Turkey's post-hoc analysis. Positively skewed variables were log transformed for statistical analysis but results are expressed in natural units. A probability of Ͻ0.05 was considered statistically significant. All statistical calculations were performed on a microcomputer using a commercially available statistical package (SPSS version 8.0 for Windows).
Results
Sixteen patients with MHT were compared with 16 patients with EHT and 32 normotensive healthy controls. Clinical features of the study population are summarised in Table 1 .
There were no significant differences in age, sex or racial distribution between the three groups studied. Antihypertensive treatment was used by only three individuals in the MHT group: metoprolol, nifedipine, valsartan, moxonidine and minoxidil (all in one patient); amlodipine (one patient); lacidipine (one patient). No patients in either the EHT or the normotensive control groups were on antihypertensive drugs.
As expected, mean systolic blood pressure, diastolic blood pressure and pulse pressure levels were highest in the MHT group, intermediate in the EHT groups and lowest in the normotensive controls (Table 1) . Patients with MHT had significantly higher mean serum creatinine levels compared with the EHT and normotensive control group.
vWf levels were raised in the MHT group (P = 0.017), compared with either of the other two groups (Table 2) . LHP levels were significantly elevated in both hypertensive groups (P Ͻ 0.001) but there was no statistically significant difference in mean LHP levels between the MHT and EHT groups.
Discussion
In view of the rarity of the condition in most developed countries, there are limited data on the pathophysiological mechanisms in MHT. This con- Continuous variables expressed as mean (95% confidence interval) and compared with ANOVA and Tukey's test *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 vs controls;
001 vs essential hypertension. a NA = not available, у1 cell with expected count Ͻ5. trasts with the extensive literature on the hypercoagulable state and abnormalities of oxidative stress in non-malignant, essential hypertension. 8, 9 The present study reports that vWf levels, an established marker of endothelial damage or dysfunction, 7 are significantly increased in MHT patients when compared with either healthy controls or patients with (non-malignant) EHT. These findings are in keeping with the gross fibrinoid necrosis of arterioles and vascular damage in the kidney, heart and brain seen histologically. Such damage to the vascular endothelium may promote platelet adhesion and clotting activation, consequently leading to thrombotic complications. 8, 9 However, our study suggests that although oxidative stress is present in MHT, it is no more severe than in EHT and is, therefore, probably unlikely to be responsible for the endothelial damage /dysfunction of MHT. Given the rarity of MHT, we have not noted a decline in its incidence 4 and the present study is strengthened by our recruitment of consecutive presentations with MHT to our unit over a 15-month period.
We accept that our study is limited by its crossJournal of Human Hypertension sectional design, and by the potential confounding effects of differences in renal function and medication use. It should be noted that antihypertensive drugs were used by only 3 patients with MHT. Whilst this may potentially be a confounder, we have previously shown that patients with uncontrolled hypertension (Ͼ160/90 mm Hg) would exhibit abnormalities of endothelial markers, irrespective of whether or not they were receiving antihypertensive therapy. 10 In addition, chronic renal impairment is usually associated with increased oxidative stress and high levels of LHP, 11 but this is unlikely to explain why levels are not higher in MHT than in EHT. Unfortunately, we do not have additional data on other markers of oxidative stress, nor do we have effects of treatment -we do accept that oxidative stress can be quantified in many different ways, as with different plasma markers reflecting other systems (eg coagulation, fibrinolysis, platelets etc) and furthermore, MHT patients are often treated with various different drugs, often with (many) changes in doses/drugs to reduce their blood pressure, and these may have confounding effects.
In conclusion, endothelial damage (raised vWf) was more evident in MHT compared with both normotensive controls and with non-malignant hypertension, whilst oxidative stress (raised LHP) was increased to a similar extent in both hypertension groups when compared with normotensive controls. These observations raise the possibility abnormal oxidative stress is probably not the mechanism responsible for the endothelial damage seen in malignant phase hypertension.
